Temporal trends in the burden of heart failure

Chan, Daniel; Kerr, Andrew; Doughty, Rob

doi:10.1111/imj.15253

Cited by 19 publications

(14 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HF is a kind of fatal disease with the majority of morbidity and mortality worldwide 82–84 . Existing methods have been used for the prevention and treatment of heart failure, but the deficiencies are non‐negligible.…”

Section: Discussionmentioning

confidence: 99%

“…HF is a kind of fatal disease with the majority of morbidity and mortality worldwide. [82][83][84] Existing methods have been used for the prevention and treatment of heart failure, but the deficiencies are non-negligible. For example, conservative therapy that only relies on the patient's dietary and emotional adjustment is a drop in the bucket.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in implantable hydrogels for treating heart failure

Wan

Sun

Zhang

et al. 2022

J of Applied Polymer Sci

View full text Add to dashboard Cite

Heart failure (HF) is an irreversible disease characterized by the reducing capacity of blood supply as a consequence of cardiomyocyte death and deteriorated fibrosis. There is a lack of effective treatment for heart failure other than a heart transplant, and thus significant resources have been dedicated to developing functional materials for cardiac tissue engineering. Implanting hydrogels in the myocardium near the myocardial infarction area can preserve cardiac function and slow the remodeling that leads to HF by providing mechanical support to the ventricular wall. Nevertheless, few reviews have been published for this promising HF treatment. Herein, we briefly discuss the classification and existing conventional treatments for HF and provide an overview of recent functional hydrogels designed for cardiac repair after myocardial infarction, including polymeric hydrogels, polymer‐cell complex hydrogels, polymer‐cytokine complex hydrogels, and polymer‐protein complex hydrogels. Key challenges and future directions for advanced hydrogels have also been discussed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Recent advances in implantable hydrogels for treating heart failure

Wan

Sun

Zhang

et al. 2022

J of Applied Polymer Sci

View full text Add to dashboard Cite

show abstract

“…Heart failure and its direct consequences represent the leading cause of death worldwide [ 115 ]. Although heart transplantation developed substantially in the last decades, there are not enough donors which would satisfy the existing needs.…”

Section: Cell Transplantation For Heart Ischemiamentioning

confidence: 99%

Regenerative Neurology and Regenerative Cardiology: Shared Hurdles and Achievements

Mitrečić

Hribljan

Jagečić

et al. 2022

IJMS

View full text Add to dashboard Cite

From the first success in cultivation of cells in vitro, it became clear that developing cell and/or tissue specific cultures would open a myriad of new opportunities for medical research. Expertise in various in vitro models has been developing over decades, so nowadays we benefit from highly specific in vitro systems imitating every organ of the human body. Moreover, obtaining sufficient number of standardized cells allows for cell transplantation approach with the goal of improving the regeneration of injured/disease affected tissue. However, different cell types bring different needs and place various types of hurdles on the path of regenerative neurology and regenerative cardiology. In this review, written by European experts gathered in Cost European action dedicated to neurology and cardiology-Bioneca, we present the experience acquired by working on two rather different organs: the brain and the heart. When taken into account that diseases of these two organs, mostly ischemic in their nature (stroke and heart infarction), bring by far the largest burden of the medical systems around Europe, it is not surprising that in vitro models of nervous and heart muscle tissue were in the focus of biomedical research in the last decades. In this review we describe and discuss hurdles which still impair further progress of regenerative neurology and cardiology and we detect those ones which are common to both fields and some, which are field-specific. With the goal to elucidate strategies which might be shared between regenerative neurology and cardiology we discuss methodological solutions which can help each of the fields to accelerate their development.

show abstract

“…Сердечная недостаточность (СН), получившая статус новой эпидемии в 1997 г., остается актуальной серьезной клинической проблемой и проблемой общественного здравоохранения [1]. Примерно у 50% пациентов с СН диагностируется сохраненная фракция выброса левого желудочка (ФВ ЛЖ) [2], и распространенность СН с сохраненной фракцией выброса (СНсФВ) ежегодно увеличивается примерно на 1% по сравнению с данным показателем для СН со сниженной ФВ ЛЖ [3]. При этом уровень 5-летней выживаемости больных с СНсФВ сопоставим с некоторыми видами негематологического рака [4], а стоимость лечения сопряжена с высокими экономическими затратами, составляющими 1-2% от общего бюджета здравоохранения.…”

Section: Introductionunclassified

Prognostic value of myocardial flow reserve in patients with heart failure with preserved ejection fraction

et al. 2023

View full text Add to dashboard Cite

Aim. To study the prognostic value of myocardial blood flow (MBF) and myocardial flow reserve (MFR) parameters in patients with heart failure with preserved ejection fraction (HFpEF) and non-obstructive coronary artery disease (CAD) in risk stratification of HFpEF progression during a 12-month follow-up.Materials and methods. The study included 58 patients with non-obstructive CAD and HFpEF (LVEF 62 [58; 66]%). Dynamic CZT-SRECT was used to evaluate MFR and MBF at rest (rest-MBF) and stress (stress-MBF). NT-proBNP levels were determined by the enzyme immunoassay. Diastolic dysfunction parameters were measured using 2D transthoracic echocardiography. Left ventricular systolic global longitudinal strain (GLS) was assessed using 2D speckle tracking.Results. After a 12-month follow-up, the patients were retrospectively divided into 2 groups: group 1 (n = 11) included patients with an unfavorable course of HFpEF, group 2 (n = 47) encompassed patients with a favorable course of the disease. In group 1, the level of NT-proBNP was 3.8 times higher than in group 2 (284.5 [183.42; 716.73] and 1,071.4 [272.4; 2,168.1] pg / ml, respectively). MFR values in group 1 were lower by 45.4%(p < 0.001) than in group 2 (1.19 [0.86; 1.55] vs. 2.18 [1.7; 2.55], respectively). In group 1, rest-MBF levels were higher by 23.6% (p = 0.046) and stress-MBF was lower by 28.2% (p = 0.046) than in group 2. The multivariate regression analysis revealed that NT-proBNP levels (odds ratio (OR) 3.23; p = 0.008), GLS (OR 2.27; p = 0.012), and MFR (OR 8.09; p < 0.001) were independent predictors of adverse outcomes in HFpEF. Based on the ROC analysis, MFR levels ≤ 1.62 (AUC = 0.827; p < 0.001), GLS ≤–18 (AUC = 0.756; p = 0.002), and NT-proBNP≥ 760.5 pg / ml (AUC = 0.708; p = 0.040) may be considered as markers of adverse outcomes. However, the combined determination of NT-proBNP and MFR had a greater significance (AUC 0.935; p < 0.001) in risk stratification compared with the monomarker model, while the addition of GLS did not increase the significance of the analysis.Conclusion. Levels of NT-proBNP, GLS, and MFR may be used as non-invasive markers of an adverse course of HFpEF in patients with non-obstructive CAD, while the combined determination of NT-proBNP and MBF increases the prognostic value of the analysis.

show abstract

Temporal trends in the burden of heart failure

Cited by 19 publications

References 45 publications

Recent advances in implantable hydrogels for treating heart failure

Recent advances in implantable hydrogels for treating heart failure

Regenerative Neurology and Regenerative Cardiology: Shared Hurdles and Achievements

Prognostic value of myocardial flow reserve in patients with heart failure with preserved ejection fraction

Contact Info

Product

Resources

About